Ignite Creation Date:
2025-12-25 @ 1:25 AM
Ignite Modification Date:
2025-12-26 @ 6:07 AM
Study NCT ID:
NCT00905593
Status:
APPROVED_FOR_MARKETING
Last Update Posted:
2012-07-18
First Post:
2009-05-18
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Nilotinib in Adult Patients With Imatinib-resistant or Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase
Sponsor:
Novartis Pharmaceuticals
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2008-09
Start Date Type:
None
Primary Completion Date:
2011-04
Primary Completion Date Type:
ESTIMATED
Completion Date:
None
Completion Date Type:
None
First Submit Date:
2009-05-18
First Submit QC Date:
None
Study First Post Date:
2009-05-20
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2012-07-17
Last Update Post Date:
2012-07-18
Last Update Post Date Type:
ESTIMATED